FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892022984> ?p ?o ?g. }

• W2892022984 endingPage "9507" @default.
• W2892022984 startingPage "9507" @default.
• W2892022984 abstract "9507 Background: PD-1 pathway inhibitors have shown significant activity in the treatment of advanced cutaneous melanoma. Their role in UM has not yet been well characterized. UM has molecular, pathogenic and clinical features distinct from cutaneous melanoma, including a low overall mutation burden, rare BRAF V600 and NRAS mutations, and a propensity for liver metastasis. In this series, we further investigate the efficacy and safety of PD-1 blockade in metastatic UM patients (pts). Methods: We analyzed a multicenter retrospective series of stage IV UM pts treated with antibodies against PD-1 (pembrolizumab, nivolumab) or its ligand, PD-L1 (atezolizumab). Tumor responses were evaluated by RECIST v1.1, and adverse events by CTCAE v4.0. Survival intervals were calculated using the Kaplan-Meier method. Demographic and clinical variables associated with tumor response and survival were investigated. Results: We retrospectively identified 58 pts across 9 academic institutions. Fifty-four (93%) pts had ECOG performance status 0 or 1, and 52 (90%) had liver metastases. Seven (12%) were treatment-naïve and 36 (62%) had received prior ipilimumab. Forty (69%) received pembrolizumab, 16 (28%) received nivolumab, and 2 (3%) received atezolizumab. Objective response rate (ORR) was 3% (95% confidence interval [CI] 0-8.4%). Stable disease greater than 6 months was observed in 4 (7%) pts. Median progression-free survival (PFS) was 2.7 months (95% CI 2.4-3.3). Median overall survival (OS) was 9.5 months (95% CI 5.5-15). There was no significant association between improved PFS or OS and age, sex, metastatic site or response to prior ipilimumab. PD-1/PD-L1 blockade was well tolerated; 7 (12%) pts reported grade 3 adverse events (AEs) of colitis, fatigue, nausea, vomiting, hyperbilirubinemia or lymphopenia, and no grade 4 or 5 AEs were reported. No pts discontinued therapy due to toxicity. Conclusions: In this largest series to date of UM pts treated with PD-1/PD-L1 antibodies, treatment was safe but rarely conferred durable responses. Predictive biomarkers and other immune or targeted therapies should be further investigated to improve clinical outcomes." @default.
• W2892022984 created "2018-09-27" @default.
• W2892022984 creator A5000401547 @default.
• W2892022984 creator A5008479799 @default.
• W2892022984 creator A5011325668 @default.
• W2892022984 creator A5025067315 @default.
• W2892022984 creator A5025872938 @default.
• W2892022984 creator A5026678528 @default.
• W2892022984 creator A5035762857 @default.
• W2892022984 creator A5039301683 @default.
• W2892022984 creator A5040291209 @default.
• W2892022984 creator A5041066193 @default.
• W2892022984 creator A5047177507 @default.
• W2892022984 creator A5054617686 @default.
• W2892022984 creator A5072582710 @default.
• W2892022984 creator A5075566772 @default.
• W2892022984 creator A5086473468 @default.
• W2892022984 creator A5088042471 @default.
• W2892022984 date "2016-05-20" @default.
• W2892022984 modified "2023-10-07" @default.
• W2892022984 title "Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM)." @default.
• W2892022984 doi "https://doi.org/10.1200/jco.2016.34.15_suppl.9507" @default.
• W2892022984 hasPublicationYear "2016" @default.
• W2892022984 type Work @default.
• W2892022984 sameAs 2892022984 @default.
• W2892022984 citedByCount "5" @default.
• W2892022984 countsByYear W28920229842017 @default.
• W2892022984 countsByYear W28920229842020 @default.
• W2892022984 crossrefType "journal-article" @default.
• W2892022984 hasAuthorship W2892022984A5000401547 @default.
• W2892022984 hasAuthorship W2892022984A5008479799 @default.
• W2892022984 hasAuthorship W2892022984A5011325668 @default.
• W2892022984 hasAuthorship W2892022984A5025067315 @default.
• W2892022984 hasAuthorship W2892022984A5025872938 @default.
• W2892022984 hasAuthorship W2892022984A5026678528 @default.
• W2892022984 hasAuthorship W2892022984A5035762857 @default.
• W2892022984 hasAuthorship W2892022984A5039301683 @default.
• W2892022984 hasAuthorship W2892022984A5040291209 @default.
• W2892022984 hasAuthorship W2892022984A5041066193 @default.
• W2892022984 hasAuthorship W2892022984A5047177507 @default.
• W2892022984 hasAuthorship W2892022984A5054617686 @default.
• W2892022984 hasAuthorship W2892022984A5072582710 @default.
• W2892022984 hasAuthorship W2892022984A5075566772 @default.
• W2892022984 hasAuthorship W2892022984A5086473468 @default.
• W2892022984 hasAuthorship W2892022984A5088042471 @default.
• W2892022984 hasConcept C121608353 @default.
• W2892022984 hasConcept C126322002 @default.
• W2892022984 hasConcept C143998085 @default.
• W2892022984 hasConcept C197934379 @default.
• W2892022984 hasConcept C21790070 @default.
• W2892022984 hasConcept C2775949291 @default.
• W2892022984 hasConcept C2776694085 @default.
• W2892022984 hasConcept C2777658100 @default.
• W2892022984 hasConcept C2777701055 @default.
• W2892022984 hasConcept C2779984678 @default.
• W2892022984 hasConcept C2780030458 @default.
• W2892022984 hasConcept C2780057760 @default.
• W2892022984 hasConcept C2780739268 @default.
• W2892022984 hasConcept C2781187634 @default.
• W2892022984 hasConcept C2781433595 @default.
• W2892022984 hasConcept C31760486 @default.
• W2892022984 hasConcept C502942594 @default.
• W2892022984 hasConcept C526805850 @default.
• W2892022984 hasConcept C535046627 @default.
• W2892022984 hasConcept C71924100 @default.
• W2892022984 hasConceptScore W2892022984C121608353 @default.
• W2892022984 hasConceptScore W2892022984C126322002 @default.
• W2892022984 hasConceptScore W2892022984C143998085 @default.
• W2892022984 hasConceptScore W2892022984C197934379 @default.
• W2892022984 hasConceptScore W2892022984C21790070 @default.
• W2892022984 hasConceptScore W2892022984C2775949291 @default.
• W2892022984 hasConceptScore W2892022984C2776694085 @default.
• W2892022984 hasConceptScore W2892022984C2777658100 @default.
• W2892022984 hasConceptScore W2892022984C2777701055 @default.
• W2892022984 hasConceptScore W2892022984C2779984678 @default.
• W2892022984 hasConceptScore W2892022984C2780030458 @default.
• W2892022984 hasConceptScore W2892022984C2780057760 @default.
• W2892022984 hasConceptScore W2892022984C2780739268 @default.
• W2892022984 hasConceptScore W2892022984C2781187634 @default.
• W2892022984 hasConceptScore W2892022984C2781433595 @default.
• W2892022984 hasConceptScore W2892022984C31760486 @default.
• W2892022984 hasConceptScore W2892022984C502942594 @default.
• W2892022984 hasConceptScore W2892022984C526805850 @default.
• W2892022984 hasConceptScore W2892022984C535046627 @default.
• W2892022984 hasConceptScore W2892022984C71924100 @default.
• W2892022984 hasIssue "15_suppl" @default.
• W2892022984 hasLocation W28920229841 @default.
• W2892022984 hasOpenAccess W2892022984 @default.
• W2892022984 hasPrimaryLocation W28920229841 @default.
• W2892022984 hasRelatedWork W2763149697 @default.
• W2892022984 hasRelatedWork W2800311363 @default.
• W2892022984 hasRelatedWork W2840847570 @default.
• W2892022984 hasRelatedWork W2968490685 @default.
• W2892022984 hasRelatedWork W3000961096 @default.
• W2892022984 hasRelatedWork W3030742570 @default.
• W2892022984 hasRelatedWork W4221003897 @default.
• W2892022984 hasRelatedWork W4223439264 @default.
• W2892022984 hasRelatedWork W4225133894 @default.

• next